UPDATE: SVB Leerink On Amarin: Firm Sees Europe As 'A Billion-Dollar Market Opportunity For Vazkepa' But Slightly Cautious On U.S. Vascepa Amidst Generic Erosion; Notes 'Early Indicators Show New U.S. Go-To-Market Strategy Is Gaining Traction'